Cytocom, a private clinical-stage biopharmaceutical company, agreed to acquire ImQuest Life Sciences, a research and development company focused specifically on cancer, inflammation and infectious disease treatments, including its subsidiaries in an all-stock transaction. Financial terms were not disclosed. "The acquisition of the ImQuest business unit solidly supports our vision of strategic growth for Cytocom. Cytocom already has four Phase 3-ready clinical programs for Crohn's disease, fibromyalgia, multiple sclerosis and pancreatic cancer in our pipeline and other assets in earlier stages of clinical development. With ImQuest Life Sciences, and its subsidiaries, we have not only strengthened and expanded our internal drug development program with new assets, but also secured revenue-generating operations, scientific resources, and tools and capacity that we can harness to further advance our mission to develop new immunotherapies targeting cancers, infectious diseases, and autoimmune disorders," Michael K. Handley, Cytocom CEO.